Evidence map›Paper›PMID 37615836›Full record

ArticleDermatology and therapy2023

Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis.

Shawn G Kwatra, Danielle Rodriguez, Carla Dias-Barbosa, Ismail Budhiarso, Fatoumata Fofana, Margaret Vernon, Sylvie Gabriel, Christophe Piketty, Jorge Puelles

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Dermatology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03181503 (A Study to Assess the Safety and Efficacy of Nemolizumab), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03181503 phase2completednot on this map

A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN)

TypeinterventionalSponsorGalderma R&DRan2017 to 2018Enrolled70ConditionsPrurigo NodularisArmsCD14152 Dose A, CD14152 placebo
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Shawn G KwatraDepartment of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-3736-1515
Danielle RodriguezEvidera, 615 2nd Ave Ste 500, Seattle, WA, 98104, USA. Danielle.Rodriguez@evidera.com.ORCID http://orcid.org/0000-0002-1135-6999
Carla Dias-BarbosaEvidera, Ivry-Sur-Seine, France.ORCID http://orcid.org/0000-0003-4701-8825
Ismail BudhiarsoEvidera, 615 2nd Ave Ste 500, Seattle, WA, 98104, USA.ORCID http://orcid.org/0000-0002-8598-1287
Fatoumata FofanaEvidera, Bennekom, The Netherlands.ORCID http://orcid.org/0000-0003-3051-0098
Margaret VernonEvidera, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3027-3467
Sylvie GabrielGalderma, La Tour-de-Peilz, Switzerland.ORCID http://orcid.org/0000-0002-7525-4510
Christophe PikettyGalderma, La Tour-de-Peilz, Switzerland.ORCID http://orcid.org/0000-0002-9969-2478
Jorge PuellesGalderma, La Tour-de-Peilz, Switzerland.ORCID http://orcid.org/0000-0003-3493-1252
Galderma (Switzerland) · CHIthaka Harbors · USJohns Hopkins University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionValidated patient report tools for quantifying patient experiences of itch in prurigo nodularis (PN) are limited. This study aimed to evaluate the validity of the 11-point peak pruritus numerical rating scale (PP NRS) as a single-item patient-reported outcome (PRO) measure for assessing itch severity in PN.

methodsContent validity of the PP NRS was evaluated through qualitative interviews with adults with PN. The PP NRS was then psychometrically evaluated using data from a placebo-controlled trial of nemolizumab in adults with PN, during which patients completed the PP NRS daily. Meaningful within-patient change was estimated from the qualitative interviews and by anchor- and distribution-based analyses of trial data.

resultsThe interview participants (N = 21) all understood the PP NRS and reported itch as their worst symptom overall. The PP NRS showed good test-retest reliability and demonstrated convergent validity and known-groups validity. PP NRS scores improved more in patients classified as "improved" on other clinical outcome measures than in those classified as "worsened/unchanged". Triangulation of the different estimates identified a 2- to 5-point decrease in PP NRS score as a meaningful within-patient change threshold.

conclusionThe PP NRS is a content-valid and reliable PRO measure for quantifying itch severity in adults with PN in clinical trials. TRIAL REGISTRATION NUMBER: NCT03181503.

Indexed as

ItchNodular prurigoOutcome measurementPatientsPruritusQualitative researchQuality of life

Identifiers

PMID37615836
PMCPMC10539229
OpenAlexW4386117139

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.